References
- Aliberti S, Goeminne PC, O’Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. The Lancet Respiratory Medicine. 2022;10: 298–306. doi:10.1016/S2213-2600(21)00277-0
- Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ. Bronchiectasis. Nature Reviews Disease Primers. 2018;4: 45. doi:10.1038/s41572-018-0042-3
- Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. The International Journal of Tuberculosis and Lung Disease. 2015;19: 610–619. doi:10.5588/ijtld.14.0613
- Wang H, Ji XB, Mao B, Li CW, Lu HW, Xu JF. Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. BMJ Open. 2018;8: e014613. doi:10.1136/bmjopen-2016-014613
- Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. European Respiratory Journal. 2014;43(5): 1357–1367. doi:10.1183/09031936.00026313
- Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index: an international derivation and validation study. American Journal of Respiratory and Critical Care Medicine. 2014;189(5): 576–585. doi:10.1164/rccm.201309-1575OC
- Saleh AD, Chalmers JD, De Soyza A, Fardon TC, Koustas SO, Scott J, et al. The heterogeneity of systemic inflammation in bronchiectasis. Respiratory Medicine. 2017;127: 33–39. doi:10.1016/j.rmed.2017.04.009
- Lee SJ, Kim HJ, Kim JY, Ju S, Lim S, Yoo JW, et al. Serum albumin and disease severity of non-cystic fibrosis bronchiectasis. Respiratory Care. 2017;62: 1075–1084. doi:10.4187/resp-care.05276
- Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68: 670–676. doi:10.1136/thoraxjnl-2012-201871
- Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74: 1–69. doi: 10.1136/tho-raxjnl-2018-212463. PMID: 30545985.
- Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS Randomized Controlled Trial. JAMA. 2013;309(12): 1260–1267. doi:10.1001/jama.2013.2290
- Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research. 2018;5: e000348. doi:10.1136/bmjresp-2018-000348
- Wagner C, Dati F. Fibrinogen. In: Thomas L (ed.)Clinical laboratory diagnostics. Frankfurt: TH-Books Verlagsgesell-schaft; 1998. p. 609–612.
- Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematologica. 1957;17: 237–246. doi:10.1159/000205234
- Jacobsson KI. Studies on the determination of fibrinogen in human blood plasma. II. Studies on the trypsin and plasmin inhibitors in human blood serum. Scandinavian Journal of Clinical and Laboratory Investigation. 1955;7: 7–13.
- Fuschillo S, de Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. European Respiratory Journal. 2008;31(2): 396–406. doi:10.1183/09031936.00069007
- Hsieh MH, Fang YF, Chen GY, Chung FT, Liu YC, Wu CH, et al. The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis. Pulmonary Medicine. 2013;2013: 795140. doi:10.1155/2013/795140
- Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Lange P, et al. InforMing the PAthway of COPD treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respiratory Research. 2021;22: 130. doi:10.1186/s12931-020-01578-8
- Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74: 439–446. doi:10.1136/thoraxjnl-2018-211855
- Lee SJ, Jeong JH, Heo M, Ju S, Yoo J-W, Jeong YY, et al. Serum fibrinogen as a biomarker for disease severity and exacerbation in patients with non-cystic fibrosis bronchiectasis. Journal of Clinical Medicine. 2022;11: 3948. doi:10.3390/jcm11143948
- Coban H, Gungen AC. Is there a correlation between new scoring systems and systemic inflammation in stable bronchiectasis? Canadian Respiratory Journal: Journal of the Canadian Thoracic Society. 2017;2017: 9874068. doi:10.1155/2017/9874068
- Gaga M, Bentley AM, Humbert M, Barkans J, O’Brien F, Wathen CG, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53(8): 685–691. doi:10.1136/thx.53.8.685
- Bizymi N, Matthaiou AM, Pitsidianakis G, Antoniou K, Tzanakis N. Fibrinogen and fractional exhaled nitric oxide as potential markers of lung functional impairment in clinically stable non-cystic fibrosis bronchiectasis. European Respiratory Journal. 2023;62(Suppl 67): A2854. doi:10.1183/13993003.con-gress-2023